CA3123493C - Molecules de liaison a l'antigene cd28 agonistes de ciblage de tumeurs - Google Patents

Molecules de liaison a l'antigene cd28 agonistes de ciblage de tumeurs

Info

Publication number
CA3123493C
CA3123493C CA3123493A CA3123493A CA3123493C CA 3123493 C CA3123493 C CA 3123493C CA 3123493 A CA3123493 A CA 3123493A CA 3123493 A CA3123493 A CA 3123493A CA 3123493 C CA3123493 C CA 3123493C
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
antigen binding
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3123493A
Other languages
English (en)
Other versions
CA3123493A1 (fr
Inventor
Guy Georges
Thomas Hofer
Ralf Hosse
Christian Klein
Ekkehard Moessner
Johannes Sam
Pablo Umana
Jenny Tosca THOM
Stephan GASSER
Jean-Baptiste Pierre Vallier
Tanja Fauti
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority claimed from PCT/EP2019/086143 external-priority patent/WO2020127618A1/fr
Publication of CA3123493A1 publication Critical patent/CA3123493A1/fr
Application granted granted Critical
Publication of CA3123493C publication Critical patent/CA3123493C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des molécules de liaison à un antigène agoniste bispécifique de ciblage de tumeurs, caractérisées par une liaison monovalente à CD28, des procédés pour leur production, des compositions pharmaceutiques contenant ces anticorps, et leurs procédés d'utilisation.
CA3123493A 2018-12-21 2019-12-19 Molecules de liaison a l'antigene cd28 agonistes de ciblage de tumeurs Active CA3123493C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18215121 2018-12-21
EP18215121.7 2018-12-21
EP19187709.1 2019-07-23
EP19187709 2019-07-23
EP19196006 2019-09-06
EP19196006.1 2019-09-06
PCT/EP2019/086143 WO2020127618A1 (fr) 2018-12-21 2019-12-19 Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs

Publications (2)

Publication Number Publication Date
CA3123493A1 CA3123493A1 (fr) 2020-06-25
CA3123493C true CA3123493C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
US12600781B2 (en) Tumor-targeted agonistic CD28 antigen binding molecules
US20200223925A1 (en) Tumor-targeted superagonistic cd28 antigen binding molecules
US12049515B2 (en) Agonistic CD28 antigen binding molecules targeting Her2
WO2021260064A1 (fr) Molécules bispécifiques de liaison à l'antigène anti-cd3/anti-cd28
US20240368309A1 (en) Agonistic cd28 antigen binding molecules targeting epcam
US20220098305A1 (en) Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
CA3123493C (fr) Molecules de liaison a l'antigene cd28 agonistes de ciblage de tumeurs
RU2837821C1 (ru) Нацеленные на опухоль агонистические cd28-антигенсвязывающие молекулы
RU2852151C1 (ru) Агонистические cd28-антигенсвязывающие молекулы, нацеленные на her2
RU2808030C2 (ru) Нацеленные на опухоль агонистические cd28-антигенсвязывающие молекулы
HK40108448A (zh) 靶向肿瘤的激动性cd28抗原结合分子
HK40128000A (zh) 靶向肿瘤的激动性cd28抗原结合分子
HK40059019A (en) Tumor-targeted agonistic cd28 antigen binding molecules
BR112021012101B1 (pt) Molécula de ligação ao antígeno agonístico cd28 biespecífico, composição farmacêutica e uso da molécula de ligação ao antígeno agonístico cd28 biespecífico